GI-SARS-2 - Gastrointestinal manifestations of SARS-CoV-2, relevance to viral replication, spread and pathogenesis.

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:5 publications

Grant number: 01KI20198A

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $249,557.49
  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principal Investigator

    N/A

  • Research Location

    Germany
  • Lead Research Institution

    Universität Heidelberg
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Although there are accumulating evidence that the intestinal epithelium is infected by SARS-CoV-2, the importance of this enteric phase for virus-induced pathologies, spreading and prognosis remain unknown. Here, we will engage in the comprehensive analysis of SARS-CoV-2 life-cycle in the human intestinal epithelium. (1) we will evaluate if there are infectious virus particles in stool. (2) we will develop standardized protocols to establish a robust measure for enteric virus shedding. (3) in organoids models, we will characterize how SARS-CoV-2 infects, replicates and is released from intestinal epithelial cells. This will provide the molecular basis of the enteric lifecycle and will enable us to determine the origin of the enteric phase (fecal/oral transmission vs. spreading from lung to gut). To these goals, we will exploit a pipeline combining single cell sequencing and spatial transcriptomics which we developed to study host-virus interaction. Combined with in-situ measurement of immune response in biopsies, we will define whether exacerbated gut inflammation contributes to the lung pathology observed in patients through cytokine storm-induced cytopathic effects. We anticipate that understanding the enteric phase of SARS-CoV-2 will provide us with critical pieces of evidence to outline novel perspectives to treat the disease and eradicate the virus. Most importantly, quantifying the relevance of fecal transmission and its link to SARS-CoV-2 etiology is urgently needed to implement epidemiological and societal measures aiming at monitoring and controlling the virus.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING.

Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.

TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells.

Single-cell analyses reveal SARS-CoV-2 interference with intrinsic immune response in the human gut.

SARS-CoV-2 infection remodels the host protein thermal stability landscape.